Stay updated on Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page.

Latest updates to the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check20 days agoChange DetectedRemoval of the government funding lapse notice from the page. The banner about potential information delays and links to operating status updates is no longer displayed.SummaryDifference0.3%

- Check34 days agoChange DetectedOnly routine metadata updates are visible, such as updated last-update dates and timestamps; core content, eligibility criteria, endpoints, and participation instructions remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check48 days agoChange DetectedUpdated biosimilar names and related dates; removed older date entries to reflect current information.SummaryDifference2%

- Check63 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference2%

- Check70 days agoChange DetectedUpdate: version from v3.0.2 to v3.1.0, indicating a new release.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page.